Castle Biosciences
CSTL
153 hedge funds and large institutions have $514M invested in Castle Biosciences in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 55 reducing their positions, and 26 closing their positions.
518% more call options, than puts
Call options by funds: $946K | Put options by funds: $153K
1.05% more ownership
Funds ownership: 83.11% → 84.15% (+1%)
7% less repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 55
3% less funds holding
Funds holding: 157 → 153 (-4)
10% less capital invested
Capital invested by funds: $569M → $514M (-$54.2M)
12% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 26
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
+$11M |
| 2 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$6.56M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$6.54M |
| 4 |
DM
Deerfield Management
New York
|
+$6.31M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.77M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$7.58M |
| 3 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$5.28M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.2M |
| 5 |
Morgan Stanley
New York
|
-$3.19M |
CSTL Hedge Fund Activity: Q4 2022 in Review
153 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q4 2022, worth a combined $514M — down 9.5% from $569M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CSTL and 23 opened new positions — a net loss of 3 holders — while 55 trimmed existing stakes and 51 added.
The largest buyer was Principal Financial Group, adding an estimated $11M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $7.77M sold.
- 153 institutional investors held Castle Biosciences (CSTL) as of Q4 2022, down from 157 in Q3 2022.
- Funds reported $514M of Castle Biosciences stock for Q4 2022, down 9.5% quarter-over-quarter.
- 23 funds opened new Castle Biosciences positions in Q4 2022 and 26 closed out, a net change of -3 holders.
- The largest Castle Biosciences buyer in Q4 2022 was Principal Financial Group, an estimated $11M added.
- The largest Castle Biosciences seller in Q4 2022 was Soleus Capital Management, an estimated $7.77M sold.
Based on aggregated 13F filings for Q4 2022.